|
**Overview**: Hepatitis B Genotyping PCR Panel**Introduction**: The Hepatitis B Genotyping PCR Panel is a diagnostic tool designed to detect HBV genotype and resistance using serum samples. In India, HBV genotypes A, C, D predominate (D most common ~60 percent), influencing disease progression and treatment response (genotype D associated with higher HCC risk). Resistance mutations (e.g., rtM204V/I) emerge during lamivudine therapy. High morbidity from under-testing in chronic HBV patients, limited genotyping labs, delayed tenofovir switch leading to virologic failure or HCC. Per microbiology practices aligned with ICMR and National Viral Hepatitis Control Programme guidelines, the test employs PCR for HBV genotype and drug resistance mutations over 1-2 days with high accuracy, valuable for personalized therapy in chronic HBV. This diagnostic falls under viral resistance screening and targets chronic HBV patients on therapy or with high viral load, addressing accurate detection to guide entecavir/tenofovir. With elevated morbidity due to under-testing, the test supports public health efforts by enabling precise genotyping/resistance profiling and reducing HBV complications. Its serum-based approach ensures reliable molecular analysis.**Other Names**: Hep B Geno Pnl.**FDA Status**: FDA approved, CLIA certified for microbiology/oncology, compliant with 2025 standards.**Historical Milestone**: HBV genotyping/resistance PCR; in India, used in liver clinics.**Purpose**: The test assesses 2 parameters including HBV genotype to guide viral assessment, detect resistance, inform antiviral therapy.**Test Parameters**: 1. HBV Genotype, 2. Drug Resistance Mutations.**Pretest Condition**: No fasting required; patients should have chronic HBV or treatment history.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on HBV duration, treatment, liver function.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected resistance including treatment failure, benefits of genotyping, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low viral load can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Genotype D or resistance mutations guide therapy choice, necessitating specialist input.**Specialist Consultation**: Hepatologists should be consulted for management.**Additional Supporting Tests**: HBV DNA viral load for confirmation.**Test Limitations**: Detects common mutations; comprehensive approach required.**References**: Indian Journal of Medical Microbiology 2024, HBV Studies India 2023. |
